CLARI.PA
BuySecond WindFLAGClariane SE · Healthcare · France · $1.6B · Avg Vol: $1M/d
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
Clariane has value V63 and momentum M63, but quality at Q47 is below the calibrated floor, and the insider buy rounds to nil, so stage one fails.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT CLARIANE SE
Read
Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 4.4B | 5.0B | 5.3B | 5.3B | 6.2% | 5.3B | 5.4B | 5.6B | 2.8% |
| EPS (EUR) | 0.54 | 0.06 | -0.30 | -0.24 | 0.00 | -69.9% | 0.03 | 0.00 | — | 9.3% |
| Shares | — | 357.3M | 357.3M | 355.7M | 356.5M | -0.2% | 357.3M | — | — | — |
| Debt | — | 8.3B | 8.6B | 8.0B | 7.8B | -1.9% | 8.3B | — | — | — |
| Equity | — | 3.5B | 3.6B | 3.7B | 3.6B | 0.7% | — | — | — | — |
| Op CF | — | 861.7M | 793.2M | 908.1M | 1.1B | 7.6% | 1.1B | — | — | — |
| Inv CF | — | -770.3M | -669.5M | 47.7M | 137.6M | — | — | — | — | — |
| Fin CF | — | -550.1M | -193.6M | -1.1B | -946.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLARI.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLARI.PA | Clariane SE(you) | $1.6B | 79 | Buy |
| EMEIS.PA | emeis Société anonyme | $2.4B | 58 | Hold |
| LNA.PA | LNA Santé SA | $397M | 96 | Strong Buy |
| LBIRD.PA | Lumibird SA | $651M | 82 | Strong Buy |
| VIRP.PA | Virbac SA | $3.1B | 88 | Strong Buy |
| VETO.PA | Vetoquinol SA | $946M | 97 | Strong Buy |
| BIM.PA | bioMérieux S.A. | $10.3B | 85 | Strong Buy |
| BOI.PA | Boiron SA | $509M | 99 | Strong Buy |
| ALERS.PA | Eurobio Scientific Société anonyme | $233M | 69 | Buy |
| GNFT.PA | Genfit S.A. | $835M | 36 | Hold |
Peer medians: ROE -42.5% · P/E 22.9x · Gross margin 73.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.